Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for D. Bruce Wheeler
0.00 (0.00%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.83 - 18.12
52 week 10.22 - 25.56
Open 17.91
Vol / Avg. 465,971.00/859,655.00
Mkt cap 1.24B
P/E     -
Div/yield     -
EPS -1.19
Shares 69.00M
Beta 1.64
Inst. own 91%
Feb 15, 2016
Q4 2015 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 12:01AM EST - Add to calendar
Nov 19, 2015
Momenta Pharmaceuticals Inc at Goldman Sachs US Emerging & SMID Cap Growth Conference
Nov 11, 2015
Momenta Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 4, 2015
Q3 2015 Momenta Pharmaceuticals Inc Earnings Call - Webcast
Nov 4, 2015
Q3 2015 Momenta Pharmaceuticals Inc Earnings Release
Sep 18, 2015
Momenta Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -217.83% -188.71%
Operating margin -220.35% -190.23%
EBITD margin - -173.58%
Return on average assets -26.73% -34.41%
Return on average equity -29.76% -41.41%
Employees 256 -
CDP Score - -


675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Company’s product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 53
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 61
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 68
Bio & Compensation  - Reuters